PT  - JOURNAL ARTICLE
AU  - Huang, Ziyang
AU  - Luo, Jingyuan
AU  - Li, Haoran
AU  - Cheng, Xingye
AU  - Zhang, Jialing
AU  - Tang, Hiu To
AU  - Wong, Hoi Ki
AU  - Cheung, Chun Hoi
AU  - Bian, Zhaoxiang
AU  - Lyu, Aiping
AU  - Tian, Liang
TI  - Incidence, risk factors, and clinical symptom profile of reinfection during Omicron-dominated COVID-19 outbreak in Hong Kong: A retrospective cohort study
AID  - 10.1101/2024.03.12.24303945
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.12.24303945
4099  - http://medrxiv.org/content/early/2024/03/15/2024.03.12.24303945.short
4100  - http://medrxiv.org/content/early/2024/03/15/2024.03.12.24303945.full
AB  - Background Despite the World Health Organization’s declaration of the end of the COVID-19 pandemic, reinfection persists and continues to strain the global healthcare system. With the emergence of the most recent variant of SARS-CoV-2 named JN.1, retrospective analysis of epidemiological characteristics of previous cases involving the Omicron variant is essential to provide references for preventing reinfection caused by the ongoing new SARS-Cov-2 variants.Methods This retrospective cohort study included 6325 patients infected with SARS-CoV-2 during the Omicron-dominated outbreak (from December 2021 to May 2022) in Hong Kong. Statistical analysis was conducted to demonstrate the epidemiological characteristics and a logistic regression model was utilized to identify risk factors associated with reinfection.Results The Omicron reinfection incidence was 5.18% (n = 353). No significant difference was observed in receiving mRNA (BNT162b2) vaccine and inactivated (CoronaVac) vaccine between reinfection and non-reinfection groups (p>0.05). Risk factors were identified as female gender (p<0.001), longer infection duration (p<0.05), comorbidity of eyes, ear, nose, throat disease (p<0.01), and severe post-infection impact on daily life and work (p<0.05), while ≥70 years old (p<0.05) and vaccination after primary infection (p<0.01) were associated with a lower risk of reinfection. The prevalence of most symptoms after reinfection was lower than the first infection, except for fatigue.Conclusion No significant difference in mRNA (BNT162b2) vaccine and inactivated (CoronaVac) vaccine against reinfection. Post-infection vaccination could lower the risk of reinfection, which potentially inform the development of preventive measures including vaccination policies against potential new SARS-Cov-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by the Research Grants Council of Hong Kong (Grant No. C2005-22Y), the National Natural Science Foundation of China (Grant No. 12275229), and the Hong Kong Chinese Medicine Development Fund (Grant No. 22B2/049A).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Hong Kong Baptist University waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual, de-identified patient data can be available upon request from the corresponding authors.COVID-19Coronavirus disease 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2WHOWorld Health OrganizationPCRpolymerase chain reactionRATrapid antigen testSDstandard deviationIQRinterquartile rangePSMpropensity score matchingaORadjusted odd ratiosORunadjusted odd ratios